mouse her2 Search Results


mouse her2 ecd 50714 m08h proteins  (Sino Biological)
94
Sino Biological mouse her2 ecd 50714 m08h proteins
Mouse Her2 Ecd 50714 M08h Proteins, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse her2 ecd 50714 m08h proteins/product/Sino Biological
Average 94 stars, based on 1 article reviews
mouse her2 ecd 50714 m08h proteins - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
erbb2 her2 alexa fluor 594  (R&D Systems)
90
R&D Systems erbb2 her2 alexa fluor 594
Erbb2 Her2 Alexa Fluor 594, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erbb2 her2 alexa fluor 594/product/R&D Systems
Average 90 stars, based on 1 article reviews
erbb2 her2 alexa fluor 594 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti acetyl coa carboxylase acc  (Cell Signaling Technology Inc)
92
Cell Signaling Technology Inc anti acetyl coa carboxylase acc
Anti Acetyl Coa Carboxylase Acc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti acetyl coa carboxylase acc/product/Cell Signaling Technology Inc
Average 92 stars, based on 1 article reviews
anti acetyl coa carboxylase acc - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
pcmv6 vector  (OriGene)
93
OriGene pcmv6 vector
Pcmv6 Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv6 vector/product/OriGene
Average 93 stars, based on 1 article reviews
pcmv6 vector - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
mouse her2  (Sino Biological)
95
Sino Biological mouse her2
Characterization of trastuzumab-optimal-synergistic-epitope (TOSE) -binding monoclonal antibodies. (a) Schematic workflow of trastuzumab-based synergistic functional screening of TOSE-binding antibodies (4H2, 4C9, 4G6, 5F12 and 5G9). 1st screening: ELISA binding and competitive ELISA with trastuzumab or pertuzumab; 2nd screening: binding to <t>HER2-positive</t> cells; 3rd screening: trastuzumab-based cell proliferation inhibition assay. (b) Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) showed trastuzumab-synergistic bioactivity higher than pertuzumab in the BT-474 cell proliferation inhibition assay. TRA: trastuzumab; PER: pertuzumab. (c) The antibody epitope grouping assay was performed by competitive ELISA. Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) bound to a unique epitope-TOSE, which was different from both the trastuzumab-binding epitope and pertuzumab-binding epitope. (d) The binding specificity and species cross-reactivity were determined by ELISA. 5G9 bound to HER2 protein, but not to other EGFR family members, including EGFR, HER3 and HER4. (e) The cross-species binding reactivity was determined by ELISA. 5G9 was able to bind cynomolgus HER2 protein but not murine HER2 protein. The BT-474 cell proliferation inhibition assay, antibody epitope grouping assay and the cross-reactivity assay were repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, *** P< 0.001.
Mouse Her2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse her2/product/Sino Biological
Average 95 stars, based on 1 article reviews
mouse her2 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
her2  (OriGene)
90
OriGene her2
Characterization of trastuzumab-optimal-synergistic-epitope (TOSE) -binding monoclonal antibodies. (a) Schematic workflow of trastuzumab-based synergistic functional screening of TOSE-binding antibodies (4H2, 4C9, 4G6, 5F12 and 5G9). 1st screening: ELISA binding and competitive ELISA with trastuzumab or pertuzumab; 2nd screening: binding to <t>HER2-positive</t> cells; 3rd screening: trastuzumab-based cell proliferation inhibition assay. (b) Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) showed trastuzumab-synergistic bioactivity higher than pertuzumab in the BT-474 cell proliferation inhibition assay. TRA: trastuzumab; PER: pertuzumab. (c) The antibody epitope grouping assay was performed by competitive ELISA. Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) bound to a unique epitope-TOSE, which was different from both the trastuzumab-binding epitope and pertuzumab-binding epitope. (d) The binding specificity and species cross-reactivity were determined by ELISA. 5G9 bound to HER2 protein, but not to other EGFR family members, including EGFR, HER3 and HER4. (e) The cross-species binding reactivity was determined by ELISA. 5G9 was able to bind cynomolgus HER2 protein but not murine HER2 protein. The BT-474 cell proliferation inhibition assay, antibody epitope grouping assay and the cross-reactivity assay were repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, *** P< 0.001.
Her2, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/her2/product/OriGene
Average 90 stars, based on 1 article reviews
her2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pe rat antimouse erbb2  (R&D Systems Hematology)
92
R&D Systems Hematology pe rat antimouse erbb2
Characterization of trastuzumab-optimal-synergistic-epitope (TOSE) -binding monoclonal antibodies. (a) Schematic workflow of trastuzumab-based synergistic functional screening of TOSE-binding antibodies (4H2, 4C9, 4G6, 5F12 and 5G9). 1st screening: ELISA binding and competitive ELISA with trastuzumab or pertuzumab; 2nd screening: binding to <t>HER2-positive</t> cells; 3rd screening: trastuzumab-based cell proliferation inhibition assay. (b) Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) showed trastuzumab-synergistic bioactivity higher than pertuzumab in the BT-474 cell proliferation inhibition assay. TRA: trastuzumab; PER: pertuzumab. (c) The antibody epitope grouping assay was performed by competitive ELISA. Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) bound to a unique epitope-TOSE, which was different from both the trastuzumab-binding epitope and pertuzumab-binding epitope. (d) The binding specificity and species cross-reactivity were determined by ELISA. 5G9 bound to HER2 protein, but not to other EGFR family members, including EGFR, HER3 and HER4. (e) The cross-species binding reactivity was determined by ELISA. 5G9 was able to bind cynomolgus HER2 protein but not murine HER2 protein. The BT-474 cell proliferation inhibition assay, antibody epitope grouping assay and the cross-reactivity assay were repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, *** P< 0.001.
Pe Rat Antimouse Erbb2, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe rat antimouse erbb2/product/R&D Systems Hematology
Average 92 stars, based on 1 article reviews
pe rat antimouse erbb2 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
antibodies mabs  (Sino Biological)
94
Sino Biological antibodies mabs
( A ) UV–Vis spectra showing the stepwise functionalization and bioconjugation of gold GNUs exhibiting an LSPR peak at 675 nm, PEG-functionalized GNUs, ADH-functionalized GNU-PEG with a peak at 220 nm, and <t>mAb-conjugated</t> GNU-PEG-ADH displaying a peak at 230 nm followed by a characteristic peak at 214 nm after the interaction. ( B ) Magnified view of ( A ) between 200 and 300 nm. ( C ) Magnification of ( B ) between 270 and 290 nm, where the mAb shows higher absorbance <t>than</t> <t>HER-II,</t> and the corresponding results for CA 15-3 from ( D – F ). Note the higher absorbance of CA 15-3 than the mAb.
Antibodies Mabs, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies mabs/product/Sino Biological
Average 94 stars, based on 1 article reviews
antibodies mabs - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
mg50714 ut  (Sino Biological)
95
Sino Biological mg50714 ut
( A ) UV–Vis spectra showing the stepwise functionalization and bioconjugation of gold GNUs exhibiting an LSPR peak at 675 nm, PEG-functionalized GNUs, ADH-functionalized GNU-PEG with a peak at 220 nm, and <t>mAb-conjugated</t> GNU-PEG-ADH displaying a peak at 230 nm followed by a characteristic peak at 214 nm after the interaction. ( B ) Magnified view of ( A ) between 200 and 300 nm. ( C ) Magnification of ( B ) between 270 and 290 nm, where the mAb shows higher absorbance <t>than</t> <t>HER-II,</t> and the corresponding results for CA 15-3 from ( D – F ). Note the higher absorbance of CA 15-3 than the mAb.
Mg50714 Ut, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mg50714 ut/product/Sino Biological
Average 95 stars, based on 1 article reviews
mg50714 ut - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
her2  (Sino Biological)
94
Sino Biological her2
( A ) UV–Vis spectra showing the stepwise functionalization and bioconjugation of gold GNUs exhibiting an LSPR peak at 675 nm, PEG-functionalized GNUs, ADH-functionalized GNU-PEG with a peak at 220 nm, and <t>mAb-conjugated</t> GNU-PEG-ADH displaying a peak at 230 nm followed by a characteristic peak at 214 nm after the interaction. ( B ) Magnified view of ( A ) between 200 and 300 nm. ( C ) Magnification of ( B ) between 270 and 290 nm, where the mAb shows higher absorbance <t>than</t> <t>HER-II,</t> and the corresponding results for CA 15-3 from ( D – F ). Note the higher absorbance of CA 15-3 than the mAb.
Her2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/her2/product/Sino Biological
Average 94 stars, based on 1 article reviews
her2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
erbb2 mouse cb11 igg1  (Cell Signaling Technology Inc)
92
Cell Signaling Technology Inc erbb2 mouse cb11 igg1
Biomarkers used in the study*
Erbb2 Mouse Cb11 Igg1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erbb2 mouse cb11 igg1/product/Cell Signaling Technology Inc
Average 92 stars, based on 1 article reviews
erbb2 mouse cb11 igg1 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

Image Search Results


Characterization of trastuzumab-optimal-synergistic-epitope (TOSE) -binding monoclonal antibodies. (a) Schematic workflow of trastuzumab-based synergistic functional screening of TOSE-binding antibodies (4H2, 4C9, 4G6, 5F12 and 5G9). 1st screening: ELISA binding and competitive ELISA with trastuzumab or pertuzumab; 2nd screening: binding to HER2-positive cells; 3rd screening: trastuzumab-based cell proliferation inhibition assay. (b) Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) showed trastuzumab-synergistic bioactivity higher than pertuzumab in the BT-474 cell proliferation inhibition assay. TRA: trastuzumab; PER: pertuzumab. (c) The antibody epitope grouping assay was performed by competitive ELISA. Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) bound to a unique epitope-TOSE, which was different from both the trastuzumab-binding epitope and pertuzumab-binding epitope. (d) The binding specificity and species cross-reactivity were determined by ELISA. 5G9 bound to HER2 protein, but not to other EGFR family members, including EGFR, HER3 and HER4. (e) The cross-species binding reactivity was determined by ELISA. 5G9 was able to bind cynomolgus HER2 protein but not murine HER2 protein. The BT-474 cell proliferation inhibition assay, antibody epitope grouping assay and the cross-reactivity assay were repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, *** P< 0.001.

Journal: EBioMedicine

Article Title: A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

doi: 10.1016/j.ebiom.2020.102996

Figure Lengend Snippet: Characterization of trastuzumab-optimal-synergistic-epitope (TOSE) -binding monoclonal antibodies. (a) Schematic workflow of trastuzumab-based synergistic functional screening of TOSE-binding antibodies (4H2, 4C9, 4G6, 5F12 and 5G9). 1st screening: ELISA binding and competitive ELISA with trastuzumab or pertuzumab; 2nd screening: binding to HER2-positive cells; 3rd screening: trastuzumab-based cell proliferation inhibition assay. (b) Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) showed trastuzumab-synergistic bioactivity higher than pertuzumab in the BT-474 cell proliferation inhibition assay. TRA: trastuzumab; PER: pertuzumab. (c) The antibody epitope grouping assay was performed by competitive ELISA. Five monoclonal antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) bound to a unique epitope-TOSE, which was different from both the trastuzumab-binding epitope and pertuzumab-binding epitope. (d) The binding specificity and species cross-reactivity were determined by ELISA. 5G9 bound to HER2 protein, but not to other EGFR family members, including EGFR, HER3 and HER4. (e) The cross-species binding reactivity was determined by ELISA. 5G9 was able to bind cynomolgus HER2 protein but not murine HER2 protein. The BT-474 cell proliferation inhibition assay, antibody epitope grouping assay and the cross-reactivity assay were repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, *** P< 0.001.

Article Snippet: The recombinant proteins huEGFR (Cat# 10001-H02H), huHER2 (Cat# 10004-H02H), huHER3 (Cat# 10201-H02H), huHER4 (Cat# 10363-H02H), rhesus HER2 (Cat# 90020-K02H) and mouse HER2 (Cat# 50714-M02H) were purchased from Sino Biological Inc.

Techniques: Binding Assay, Functional Assay, Enzyme-linked Immunosorbent Assay, Competitive ELISA, Inhibition

5G9 and trastuzumab synergistically inhibit HER2-positive cancer cell growth. (a) Inhibition of BT-474 cell viability was examined by Cell Titer Glo after 6 days of antibody treatment. The initial antibody concentration was 100 nM for both the monoclonal antibody and the antibody combination (1:1 ratio). Growth inhibition was calculated as the fraction of viable cells in the antibody treated group compared with untreated control cells. The cell proliferation inhibition assay was repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, ** P< 0.01. TRA: trastuzumab; PER: pertuzumab. (b) Dose-effect plots and combination index (CI.) plots of the two combinations were calculated by using the method of Chou and Talalay with the commercial software Calcusyn. C.I. values for effective doses at which 50%, 75%, and 90% (ED 50 , ED 75 , and ED 90 , respectively) of cells were killed. Drug synergy was defined by C.I. values less than 1, the lower C.I. value, the more synergy. (c) Representative images from the EdU assay of BT-474 cells. The viable cells were stained blue by DAPI (blue) and the proliferation cells were stained red by EdU (red).The EdU assay was repeated three times and the representative images were shown. (d) Human breast cancer cell lines (SK-BR-3, AU-565, MCF-7) and human gastric cell lines (NCI-N87) were treated with 100 nM antibodies for 3 or 6 days and cell viability was determined by Cell Titer Glo. The experiments were repeated three times and the cell viability is shown as the mean ± SD ( n = 3). The relative HER2 expression of cell lines was detected and analyzed by flow cytometry and FlowJo software.

Journal: EBioMedicine

Article Title: A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

doi: 10.1016/j.ebiom.2020.102996

Figure Lengend Snippet: 5G9 and trastuzumab synergistically inhibit HER2-positive cancer cell growth. (a) Inhibition of BT-474 cell viability was examined by Cell Titer Glo after 6 days of antibody treatment. The initial antibody concentration was 100 nM for both the monoclonal antibody and the antibody combination (1:1 ratio). Growth inhibition was calculated as the fraction of viable cells in the antibody treated group compared with untreated control cells. The cell proliferation inhibition assay was repeated three times and the results were shown as the mean ± SD ( n = 3). Two-way ANOVA, ** P< 0.01. TRA: trastuzumab; PER: pertuzumab. (b) Dose-effect plots and combination index (CI.) plots of the two combinations were calculated by using the method of Chou and Talalay with the commercial software Calcusyn. C.I. values for effective doses at which 50%, 75%, and 90% (ED 50 , ED 75 , and ED 90 , respectively) of cells were killed. Drug synergy was defined by C.I. values less than 1, the lower C.I. value, the more synergy. (c) Representative images from the EdU assay of BT-474 cells. The viable cells were stained blue by DAPI (blue) and the proliferation cells were stained red by EdU (red).The EdU assay was repeated three times and the representative images were shown. (d) Human breast cancer cell lines (SK-BR-3, AU-565, MCF-7) and human gastric cell lines (NCI-N87) were treated with 100 nM antibodies for 3 or 6 days and cell viability was determined by Cell Titer Glo. The experiments were repeated three times and the cell viability is shown as the mean ± SD ( n = 3). The relative HER2 expression of cell lines was detected and analyzed by flow cytometry and FlowJo software.

Article Snippet: The recombinant proteins huEGFR (Cat# 10001-H02H), huHER2 (Cat# 10004-H02H), huHER3 (Cat# 10201-H02H), huHER4 (Cat# 10363-H02H), rhesus HER2 (Cat# 90020-K02H) and mouse HER2 (Cat# 50714-M02H) were purchased from Sino Biological Inc.

Techniques: Inhibition, Concentration Assay, Software, EdU Assay, Staining, Expressing, Flow Cytometry

5G9 and trastuzumab enhance cell apoptosis, HER2 internalization and disruption. (a) BT-474 cells were treated with 100 nM antibodies for 3 days. The number of viable cells was detected by Trypan Blue, and annexin-V and PI were used to stain early apoptotic cells and dead cells. TRA: trastuzumab; PER: pertuzumab. (b) BT-474 cells were treated with 100 nM antibodies for 3 days, and cell lysates were obtained and immunoblotted with a poly (ADP-ribose) polymerase (PARP) polyclonal antibody. Cleaved PARP is represented by 89 KD-fragments and full-length PARP (116 KD). (c) HER2 internalization induced by 5G9, trastuzumab or pertuzumab in SK-BR-3 cells. (d) The effect of trastuzumab on the internalization of 5G9 or pertuzumab in SK-BR-3 cells. FITClabeled 5G9 or pertuzumab was detected and analyzed by flow cytometry and FlowJo software. (e) The effect of 5G9 or pertuzumab on the internalization of trastuzumab in SK-BR-3 cells. APC labeled trastuzumab was detected and analyzed by flow cytometry and FlowJo software. (f) Effect of HER2 single agents or combination on receptor phosphorylation and downstream signaling cascade. BT-474 cells were treated with 100 nM antibodies for 3 days, and cell lysates were obtained and immunoblotted with antibodies against EGFR, p-EGFR, HER2, p-HER2, HER3, p-HER3, AKT, p-AKT, ERK, p-ERK, and GAPDH. All experiments were repeated three times and the representative images and data were shown. Two-way ANOVA, * P< 0.05, *** P< 0.001.

Journal: EBioMedicine

Article Title: A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

doi: 10.1016/j.ebiom.2020.102996

Figure Lengend Snippet: 5G9 and trastuzumab enhance cell apoptosis, HER2 internalization and disruption. (a) BT-474 cells were treated with 100 nM antibodies for 3 days. The number of viable cells was detected by Trypan Blue, and annexin-V and PI were used to stain early apoptotic cells and dead cells. TRA: trastuzumab; PER: pertuzumab. (b) BT-474 cells were treated with 100 nM antibodies for 3 days, and cell lysates were obtained and immunoblotted with a poly (ADP-ribose) polymerase (PARP) polyclonal antibody. Cleaved PARP is represented by 89 KD-fragments and full-length PARP (116 KD). (c) HER2 internalization induced by 5G9, trastuzumab or pertuzumab in SK-BR-3 cells. (d) The effect of trastuzumab on the internalization of 5G9 or pertuzumab in SK-BR-3 cells. FITClabeled 5G9 or pertuzumab was detected and analyzed by flow cytometry and FlowJo software. (e) The effect of 5G9 or pertuzumab on the internalization of trastuzumab in SK-BR-3 cells. APC labeled trastuzumab was detected and analyzed by flow cytometry and FlowJo software. (f) Effect of HER2 single agents or combination on receptor phosphorylation and downstream signaling cascade. BT-474 cells were treated with 100 nM antibodies for 3 days, and cell lysates were obtained and immunoblotted with antibodies against EGFR, p-EGFR, HER2, p-HER2, HER3, p-HER3, AKT, p-AKT, ERK, p-ERK, and GAPDH. All experiments were repeated three times and the representative images and data were shown. Two-way ANOVA, * P< 0.05, *** P< 0.001.

Article Snippet: The recombinant proteins huEGFR (Cat# 10001-H02H), huHER2 (Cat# 10004-H02H), huHER3 (Cat# 10201-H02H), huHER4 (Cat# 10363-H02H), rhesus HER2 (Cat# 90020-K02H) and mouse HER2 (Cat# 50714-M02H) were purchased from Sino Biological Inc.

Techniques: Staining, Flow Cytometry, Software, Labeling

( A ) UV–Vis spectra showing the stepwise functionalization and bioconjugation of gold GNUs exhibiting an LSPR peak at 675 nm, PEG-functionalized GNUs, ADH-functionalized GNU-PEG with a peak at 220 nm, and mAb-conjugated GNU-PEG-ADH displaying a peak at 230 nm followed by a characteristic peak at 214 nm after the interaction. ( B ) Magnified view of ( A ) between 200 and 300 nm. ( C ) Magnification of ( B ) between 270 and 290 nm, where the mAb shows higher absorbance than HER-II, and the corresponding results for CA 15-3 from ( D – F ). Note the higher absorbance of CA 15-3 than the mAb.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: ( A ) UV–Vis spectra showing the stepwise functionalization and bioconjugation of gold GNUs exhibiting an LSPR peak at 675 nm, PEG-functionalized GNUs, ADH-functionalized GNU-PEG with a peak at 220 nm, and mAb-conjugated GNU-PEG-ADH displaying a peak at 230 nm followed by a characteristic peak at 214 nm after the interaction. ( B ) Magnified view of ( A ) between 200 and 300 nm. ( C ) Magnification of ( B ) between 270 and 290 nm, where the mAb shows higher absorbance than HER-II, and the corresponding results for CA 15-3 from ( D – F ). Note the higher absorbance of CA 15-3 than the mAb.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques:

SERS signals of standard HER-II solution for before (mAb-conjugated) and after interaction at various concentrations.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: SERS signals of standard HER-II solution for before (mAb-conjugated) and after interaction at various concentrations.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques:

The trials of the SERS results of the functionalization, conjugation, and interaction steps for (GNU-mAb)-HER-II.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: The trials of the SERS results of the functionalization, conjugation, and interaction steps for (GNU-mAb)-HER-II.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques: Conjugation Assay

SERS signals of standard CA15-3 solutions for before (mAb-conjugated) and after interaction at various concentrations.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: SERS signals of standard CA15-3 solutions for before (mAb-conjugated) and after interaction at various concentrations.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques:

The trials of the SERS results of the functionalization, conjugation, and interaction steps for (GNU-mAb)-CA15-3.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: The trials of the SERS results of the functionalization, conjugation, and interaction steps for (GNU-mAb)-CA15-3.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques: Conjugation Assay

SERS signals of CA15-3 BCS samples for before (mAb-conjugated) and after interaction at various concentrations.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: SERS signals of CA15-3 BCS samples for before (mAb-conjugated) and after interaction at various concentrations.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques:

PCA plots for various stages of interaction: ( A ) GNU-mAb + HER-II, ( B ) GNU-mAb + CA15-3, and ( C ) GNU-mAb+HBS.

Journal: Biosensors

Article Title: Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum

doi: 10.3390/bios15070447

Figure Lengend Snippet: PCA plots for various stages of interaction: ( A ) GNU-mAb + HER-II, ( B ) GNU-mAb + CA15-3, and ( C ) GNU-mAb+HBS.

Article Snippet: HER-II and CA15-3 monoclonal antibodies (mAbs) were purchased from SinoBiological (10004-MM03, HER-II/ErB 2 /CD340 Antibody, Mouse Mab, and 12123-MM05, MUC1/Mucin 1/CD227 Antibody, mouse Mab, respectively; Pennsylvania, USA). summarizes the characteristics of CA15-3 and the clinical status of the corresponding BCS samples.

Techniques:

Biomarkers used in the study*

Journal: JNCI Journal of the National Cancer Institute

Article Title: Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues

doi: 10.1093/jnci/djs438

Figure Lengend Snippet: Biomarkers used in the study*

Article Snippet: Vendor Biomarkers for companion diagnostic tests Estrogen receptor-alpha (ERα) Mouse 1D5/IgG1kappa M7047 DAKO Rabbit SP1/IgG RM-9101 Thermo Scientific Progesterone receptor (PgR) Mouse PgR636/IgG1kappa M3569 DAKO Rabbit PgRA/B (C89F7) 3153 Cell Signaling Technology HER2, also known as ERBB2 Mouse CB11/IgG1 CM 076 AA Biocare Medical Rabbit polyclonal A0485 DAKO Ki67 Mouse MIB-1/IgG1kappa M7240 DAKO Rabbit SP6/IgG 9106-S0 Lab Vision Markers of cold ischaemia Beta-actin (ACTB) Rabbit 13E5/IgG 13E5/IgG Cell Signaling Technology Beta-tubulin (TUBB) Rabbit pF3/IgG 2128 Cell Signaling Technology Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Rabbit 14C10/IgG 2118 Cell Signaling Technology Histone 4 (HIST4H4) Mouse L64C1 2935 Cell Signaling Technology Histone 3 (HIST3H3) Mouse 96C10/IgG1, kappa 3680 Cell Signaling Technology Lamin A/C (LMNA) Rabbit polyclonal 2032 Cell Signaling Technology Lactate dehydrogenase A (LDHA) Rabbit IgG, C4B5 3582 Cell Signaling Technology Cytokeratin (KRT X) Mouse AE1/AE3/IgG1 M3515 DAKO Rabbit polyclonal ZO622 DAKO Markers of hypoxia Cyclin D1 (CCND1) Rabbit IgG/SP4 RM-9104 Thermo Fisher Fremont Cyclin B1 (CCNB1) Mouse GNS-11/IgG2 554178 BD Biosciences A kinase (PRKA) anchor protein 13 (AKAP13) Mouse IgG2a/ZX-18 sc-81902 Santa Cruz Biotechnology Cell division cycle 42 (CDC42) Mouse IgG3/B-8 sc-8401 Santa Cruz Biotechnology Cleaved caspase3 (CASP3) Rabbit polyclonal 9661 Cell Signaling Technology Hypoxia inducible factor 1-alpha (HIF1A) Rabbit polyclonal NB 100–449 Novus Biological Hypoxia inducible factor 2-alpha (HIF2A) Mouse ep190b/IgG1 ab8365 abcam Markers of phosphorylated proteins Phosphorylated tyrosine (4G10) Mouse IgG2b 05-1050 Millipore Markers of post-translational modification SMT3 suppressor of mif two 3 homolog 1 (SUMO1) Rabbit Y299/IgG ab32058 abcam Acetylated lysine Rabbit polyclonal, purified 9441 Cell Signaling Technology Neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) Rabbit IgG, 19E3 2754 Cell Signaling Technology Open in a separate window * Antibodies were validated and used for quantitative immunofluorescence assays as described in the Patients and Methods section.

Techniques: Diagnostic Assay, Modification, Purification